图文详情
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, both of which promote osteogenic differentiation in human periosteum-derived cells (hPDC). Consequently, Bimekizumab inhibits inflammation-driven osteogenic differentiation [1].